EU/3/18/2083

About

On 19 November 2018, orphan designation (EU/3/18/2083) was granted by the European Commission to MaaT Pharma, France, for allogeneic faecal microbiota, pooled for the treatment of graft-versus-host disease.

Key facts

Active substance
Allogeneic faecal microbiota, pooled
Disease / condition
Treatment of graft-versus-host disease
Date of first decision
19/11/2018
Outcome
Positive
EU designation number
EU/3/18/2083

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

MaaT PHARMA
317 Avenue Jean Jaurès
69007 Lyon
France
Tel: +33 7 76 15 77 10
E-mail: contact@maat-pharma.com

 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating